51³ΙΘΛΆ―Βώ

Meeting Coverage

ESC

European Society of Cardiology Congress

Oral Anticoagulation and TAVR Together: A Recipe for Trouble

Continued OAC failed to meet noninferiority in POPular PAUSE TAVI

ESC over a photo of ExCeL London conference and exhibition center.

Latest ESC Meeting Coverage

Novel Drug Reduced Triglycerides, Risk of Pancreatitis in Persistent Chylomicronemia

Benefits seen in patients with and without a genetic diagnosis

September 3, 2024
Invasive Strategy for NSTEMI in the Elderly: Fears Don't Pan Out in SENIOR-RITA

Trial paints a fuller picture of risk-benefit in complex patient population

September 3, 2024
ESC Streamlines Cardiovascular Guidelines

Afib, hypertension, and others get updates with simplifications

September 3, 2024
Afib Ablation Delivers in First Sham-Controlled Study

More conclusive evidence for benefits on Afib burden, QoL

September 2, 2024
Drug-Coated Balloon Flops for De Novo Coronary Lesions

First adequately powered randomized trial suggests larger vessel disease isn't the right fit

September 2, 2024
DOAC Monotherapy Bests Dual Antithrombotic Therapy for Afib Plus Coronary Disease

Bleeding reduced -- without risk of ischemic events -- versus dual antithrombotic in Korean trial

September 1, 2024
Nonsteroidal MRA Improves Outcomes in HFpEF, HFmrEF

Randomized trial shows benefits beyond heart failure with low ejection fraction, but not survival

September 1, 2024
Stenting, TAVR Make Sense Packaged Together for Some Patients

NOTION-3 trial informs care for those with severe AS and stable CAD

September 1, 2024
Another Trial Sides With MitraClip for Functional Mitral Regurgitation

RESHAPE-HF2 has provocative implications for a wider pool of TEER candidates

August 31, 2024
TriClip's 'Soft' Benefits Affirmed in Severe Tricuspid Regurgitation

Randomized trial "highly encouraging" for making patients feel and function better

August 31, 2024
Potassium Strategy After Cardiac Bypass Grafting Doesn't Impact Afib Risk

First randomized trial debunks common practice of tight control

August 31, 2024
Pause or Keep RAS Inhibitors Before Surgery? Take Your Pick.

Either choice is "acceptable" based on randomized study

August 31, 2024
Women's 30-Year Heart Risk Can Be Predicted by Just Three Factors

And two aren't in the standard cardiovascular risk prediction tool

August 31, 2024
Amyloidosis Drug Improves Outcomes, Survival

RNA silencer impresses with results in transthyretin amyloidosis cardiomyopathy

August 30, 2024